Jiangsu Yahong Meditech Co. Ltd.
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis … Read more
Jiangsu Yahong Meditech Co. Ltd. (688176) - Net Assets
Latest net assets as of September 2025: CN¥1.74 Billion CNY
Based on the latest financial reports, Jiangsu Yahong Meditech Co. Ltd. (688176) has net assets worth CN¥1.74 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.15 Billion) and total liabilities (CN¥412.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.74 Billion |
| % of Total Assets | 80.8% |
| Annual Growth Rate | 86.22% |
| 5-Year Change | 144.31% |
| 10-Year Change | N/A |
| Growth Volatility | 999.24 |
Jiangsu Yahong Meditech Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how Jiangsu Yahong Meditech Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangsu Yahong Meditech Co. Ltd. (2018–2024)
The table below shows the annual net assets of Jiangsu Yahong Meditech Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.97 Billion | -17.55% |
| 2023-12-31 | CN¥2.39 Billion | -13.76% |
| 2022-12-31 | CN¥2.77 Billion | -8.03% |
| 2021-12-31 | CN¥3.01 Billion | +273.58% |
| 2020-12-31 | CN¥806.50 Million | +2704.73% |
| 2019-12-31 | CN¥28.75 Million | -39.09% |
| 2018-12-31 | CN¥47.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Yahong Meditech Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 132982755043.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥570.00 Million | 28.94% |
| Other Components | CN¥2.83 Billion | 143.60% |
| Total Equity | CN¥1.97 Billion | 100.00% |
Jiangsu Yahong Meditech Co. Ltd. Competitors by Market Cap
The table below lists competitors of Jiangsu Yahong Meditech Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SK Bioscience Co Ltd
KO:302440
|
$769.70 Million |
|
Zhuzhou Hongda Electronics Corp Ltd Class A
SHE:300726
|
$769.73 Million |
|
Winall Hi tech Seed
SHE:300087
|
$769.76 Million |
|
PTT OIL+RET.BUS.-FOR-BA10
F:7F8
|
$770.02 Million |
|
SeaWorld Entertainment Inc
F:W2L
|
$769.17 Million |
|
Financial Street Holdings Co Ltd
SHE:000402
|
$768.61 Million |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
$768.43 Million |
|
Chongqing Taiji Industry Group Co Ltd
SHG:600129
|
$768.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Yahong Meditech Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,387,969,481 to 1,969,405,336, a change of -418,564,145 (-17.5%).
- Net loss of 384,063,418 reduced equity.
- Dividend payments of 2,491,031 reduced retained earnings.
- Share repurchases of 50,059,352 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-384.06 Million | -19.5% |
| Dividends Paid | CN¥2.49 Million | -0.13% |
| Share Repurchases | CN¥50.06 Million | -2.54% |
| Other Changes | CN¥18.05 Million | +0.92% |
| Total Change | CN¥- | -17.53% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Yahong Meditech Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 243.96x to 4.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥0.06 | CN¥15.25 | x |
| 2020-12-31 | CN¥1.76 | CN¥15.25 | x |
| 2021-12-31 | CN¥6.54 | CN¥15.25 | x |
| 2022-12-31 | CN¥4.83 | CN¥15.25 | x |
| 2023-12-31 | CN¥4.19 | CN¥15.25 | x |
| 2024-12-31 | CN¥3.48 | CN¥15.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Yahong Meditech Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -190.54%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.13x
- Recent ROE (-19.50%) is above the historical average (-115.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -126.95% | 0.00% | 0.00x | 1.40x | CN¥-64.66 Million |
| 2019 | -599.64% | 0.00% | 0.00x | 2.53x | CN¥-175.30 Million |
| 2020 | -30.66% | 0.00% | 0.00x | 1.05x | CN¥-327.92 Million |
| 2021 | -7.80% | -5135637.81% | 0.00x | 1.03x | CN¥-536.24 Million |
| 2022 | -8.90% | -944816.19% | 0.00x | 1.04x | CN¥-523.65 Million |
| 2023 | -16.77% | -2911.54% | 0.01x | 1.10x | CN¥-639.23 Million |
| 2024 | -19.50% | -190.54% | 0.09x | 1.13x | CN¥-581.00 Million |
Industry Comparison
This section compares Jiangsu Yahong Meditech Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,061,893,866
- Average return on equity (ROE) among peers: 4.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Yahong Meditech Co. Ltd. (688176) | CN¥1.74 Billion | -126.95% | 0.24x | $769.25 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $608.50 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $324.94 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $11.33 Billion | 18.40% | 0.22x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.30 Billion | 13.53% | 1.39x | $1.92 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $525.21 Million | 17.84% | 0.75x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $4.63 Billion | -3.44% | 1.33x | $704.71 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $325.99 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.07 Billion | 2.59% | 1.71x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $3.91 Billion | 12.94% | 0.18x | $777.45 Million |